40 results about "Heterotopic ossification" patented technology

Described are methods of inhibiting heterotopic ossification (HO) in a subject in need thereof. The methods involve administering an effective amount of a proprioception inhibitor to the subject, whereby HO is inhibited or prevented. The present invention also relates to a method of treating a subject with bone trauma. This involves administering a proprioception inhibitor to the subject under conditions effective to treat the bone trauma, where the proprioception inhibitor prevents or inhibits HO.

Presented herein are systems and methods that facilitate automated segmentation of 3D images of subjects to distinguish between regions of heterotopic ossification (HO) normal skeleton, and soft tissue. In certain embodiments, the methods identify discrete, differentiable regions of a 3D image of subject (e.g., a CT or microCT image) that may then be either manually or automatically classified as either HO or normal skeleton.

The present invention discloses a bone growth factor injection and its preparation method. It includes the following steps: firstly, preparing bone growth factor into solution or mixed suspension; then preparing heat-sensitive hydrogel carrier solution; combining above-mentioned two solutions and making them into injection liquor or freeze-dried product. After the injection is injected into the fracture zone, the coagulated gel can be quickly formed, the bone growth factor and gel composite can be retained in bone repairing zone so as to fully produce slowly-releasing effect-increasing and effect-prolonging action and can raise biological utilization rate of the bone growth factor can raise its bone-forming action.

The directional-ionizing energy emitting implant is for attachment either to natural tissue or a prosthetic device, and delivers a prescribed dosage of energy to targeted tissue. The insert device includes an energy-source material within the insert device that delivers the prescribed dosage of energy to the targeted tissue, while minimizing exposure of nontargeted tissue. The targeted tissue has a known energy-response profile and is adjacent to the targeted tissue. The energy-source material in combination with the prosthetic device defines an actual energy-delivery distribution field. The energy-delivery distribution field has a configuration similar to the known energy-responsive profile of the targeted tissue. The prescribed dosage of energy is applied from energy-source material within the insert device and directed to the targeted tissue. The prescribed energy dosage is determined by using known characteristics of the energy-source material, and by the placement of the energy-source material relative to the targeted tissue. The implant system reduces any occurrence of heterotopic ossification caused by the implant, inhibits growth or migration of benign or malignant living cells, and minimizes or even eliminates infectious processes or delayed keloid or scar formation induced from surgical placement of a functional prosthesis or fixation device, in tissue within or about the device due to its targeted therapeutic energy emission effects.

The directional-ionizing energy emitting implant is for attachment either to natural tissue or a prosthetic device, and delivers a prescribed dosage of energy to targeted tissue. The insert device includes an energy-source material within the insert device that delivers the prescribed dosage of energy to the targeted tissue, while minimizing exposure of nontargeted tissue. The targeted tissue has a known energy-response profile and is adjacent to the targeted tissue. The energy-source material in combination with the prosthetic device defines an actual energy-delivery distribution field. The energy-delivery distribution field has a configuration similar to the known energy-responsive profile of the targeted tissue. The prescribed dosage of energy is applied from energy-source material within the insert device and directed to the targeted tissue. The prescribed energy dosage is determined by using known characteristics of the energy-source material, and by the placement of the energy-source material relative to the targeted tissue. The implant system reduces any occurrence of heterotopic ossification caused by the implant, inhibits growth or migration of benign or malignant living cells, and minimizes or even eliminates infectious processes or delayed keloid or scar formation induced from surgical placement of a functional prosthesis or fixation device, in tissue within or about the device due to its targeted therapeutic energy emission effects.

The invention relates to a cervical-vertebrajoint replacement device with vertebralpartial resection. The cervical-vertebrajoint replacement device with vertebralpartial resection comprises an upper hemivertebraprosthesis, a lower hemivertebraprosthesis and a cup-and-ball-jointintervertebral discprosthesis, wherein the lower surface of the upper hemivertebraprosthesis and the upper surface of thelower hemivertebraprosthesis are each provided with a clamping groove, the upper end and the lower end of the cup-and-ball-jointintervertebral discprosthesis are each provided with a buckle for beingin buckling cooperation with the clamping groove, and the upper surface of the upper hemivertebraprosthesis and the lower surface of the lower hemivertebraprosthesis are each provided with a fixing bolt. According to the cervical-vertebrajoint replacement device with vertebralpartial resection, three parts separated combinationprostheses are adopted, the space between the upper hemivertebraprosthesis and the lower hemivertebraprosthesis is adjustable, the cervical-vertebrajoint replacement device can be used for patients with obviously-narrow partial intervertebral space and patients withcompression factors located behind the vertebral body, and the indication range of a CDA operation is widened; a space structure is a 'metal to metal' space structure, an environmental basis formed by HO is eliminated accordingly, the side effect formed by an inhibition bone of NSAIDs does not need to be considered, HO prevention can be trustingly carried out with the NSAIDs, and the occurrence rate ofheterotopic ossification is decreased.

The invention provides a method of treating heterotopic ossification in a subject in need thereof. The method comprises administering a hypoxia inducible factor-1α (Hif-1α) inhibitor to the subject. In various embodiments, the Hif-1α inhibitor is PX-478, rapamycin, or digoxin.

The present invention includes embodiments for methods and compositions that identify the presence of or risk for developing heterotopic ossification, particularly prior to mineralization of the bone. In particular embodiments, MMP-9 and / or MMP-2 agents comprising dual imaging moieties are used to identify patterns of MMP-9 and / or MMP-2 localization, respectively, that is then predictive of heterotopic ossification.

The invention relates to an artificial cervical disc plate-bone gap filling device and an artificial intervertebral disc prosthesis. The artificial cervical disc plate-bone gap filling device comprises an air bag and an end plate, wherein the air bag is arranged under the end plate, the end plate is divided into multiple independent plate pieces attached to the outer surface of the air bag, and aninjection port is formed in the air bag and communicates with the inside of the air bag; toothed bulges are arranged on the upper surfaces of the plate pieces, hydroxyapatite coatings are arranged onupper surfaces of the plate pieces, the plate pieces are made of metal, and the air bag is made of a high polymer material. The artificial cervical disc plate-bone gap filling device fills plate-bonegaps, can meet various end plate dome radians only by one prosthesis and has a wide application range and high practicability; and the device reduces polishing of the bony end plate during operation,so that the occurrence rate of fracture during operation is decreased, the bleeding amount during operation is reduced, and the occurrence rate of heterotopic ossification after operation is reducedindirectly.

The invention discloses an application of microRNA-29b in articular cartilage repair as a drug target. According to the application disclosed by the invention, the research indicates that microRNA-29b is a key miRNA for regulating the hypertrophy change of MSCs after chondrogenic differentiation, therefore, the hypertrophy of MSCs-derived cartilage cells is inhibited by virtue of an microRNA-29b inhibitor, the phenotypes of the MSCs-derived cartilage cells are stabilized, and the fibrosis and the heterotopic ossification of tissue engineering cartilages are prevented, thus further realizing tissue engineering cartilage repair, and providing a new thought for tissue engineering cartilage construction, cartilage framework material design and cartilage repair.

The present disclosure relates to an artificial ankle joint talus component and, more particularly, to an artificial ankle joint talus component including a joint surface in contact with an insert and a contact surface in contact with a bone, wherein the contact surface may be formed to be complementary to a resected surface of a talus so as to cover the entire resected surface, thereby dispersing stress, and reducing after-effects of surgery, such as osteolysis, heterotopic ossification, or the like.

The invention discloses an SDF-1 alpha / CGRP-loaded HAp-SF artificial periosteum and a preparation method thereof, and belongs to the field of orthopedic implant materials, the SDF-1 alpha and CGRP factors are added to degradable macromolecules as main raw materials, and the nHA / SF absorbable artificial periosteum loaded with SDF-1 alpha and CGPR factors is prepared by an electrostatic spinning method. The prepared artificial periosteum has the performance of loading and slowly releasing SDF-1-alpha and CGPR factors, so that the artificial periosteum has good osteogenesis and angiogenesis activity and biocompatibility. Besides, the artificial periosteum can play a barrier role in the local defect part, can effectively prevent surrounding soft tissue from growing in and heterotopic ossification from occurring, further has better mechanical strength and biodegradability, and can be used as a repairing material for bone tissue defect.

The invention discloses a heterotopic ossification CT image segmentation method and device, and a heterotopic ossification CT image segmentation three-dimensional reconstruction method and device. The segmentation method comprises the following steps: acquiring a heterotopic ossification CT image of a patient; inputting the heterotopic ossification CT image into a pre-trained CT image auto-encoder, and outputting a reconstructed CT image; subtracting the reconstructed CT image from the original heterotopic ossification CT image pixel by pixel to obtain a residual CT image; obtaining an abnormal region through noise reduction processing; transforming the abnormal region into an image mask consistent with the original heterotopic ossification CT image in size; and multiplying the image mask by the original heterotopic ossification CT image pixel by pixel to obtain a segmented abnormal image. According to the scheme, the heterotopic ossification part can be automatically segmented from the CT image, three-dimensional reconstruction of the heterotopic ossification stereoscopic view can be facilitated, the film viewing speed of doctors can be greatly improved, and low-age doctors or inexperienced people can be helped to accurately find the heterotopic ossification part.

The present invention is directed to compositions and methods for the prevention or treatment of treatment of heterotopic ossification, vascular calcification, or pathologic calcification.

This invention provides composition and methods of treating subjects with microbial infection, sepsis, wounds, heterotopic ossification, or combination thereof. In each case, the treatment methods of the present invention comprise administering ADPase-enhanced apyrase agents, alone or in combination with an antimicrobial.

The invention discloses an application of a medicine Galunissertib in preparation of a medicine for preventing traumatic ectopic ossification, and belongs to the field of medicines. The research finds that Galunissertib inhibits formation of mouse traumatic heterotopic ossification by inhibiting phosphorylation of Smad2 / 3 so as to block differentiation of stem cells mediated by a TGF-beta pathway to osteogenesis, and finally inhibits formation of mouse traumatic heterotopic ossification. At present, the participation of a TGF-beta pathway in the formation mechanism of clinical traumatic ectopic ossification is fully clarified, so that the medicine also has a good inhibition effect on ectopic ossification caused by limb fracture, joint replacement, spinal cord injury, brain injury and burn, the formation of traumatic ectopic ossification can be obviously inhibited by the dosage of 10mg / kg, the cost is low, the effect is high, and the medicine is suitable for clinical popularization and application. No toxic or side effect exists.

The present application relates to a pharmaceutical composition which can be used in a method for treating and / or preventing a patient having heterotopic ossification and / or brain tumor, the pharmaceutical composition being characterized in that the patient has an activated mutation in ALK2 protein that is a cause of heterotopic ossification or brain tumor, the amino acid residue at position-330 in ALK2 is proline, and an active ingredient of the composition is an anti-ALK2 antibody having a property to bind to ALK2, a property to crosslink with ALK2 and a property to inhibit BMP signal transfer or an antigen-binding fragment of the antibody.

The present inventors have uncovered the nature of heterotopic ossification HO progression as an excessive activation of TGF-β in recruitment of MSCs for osteogenesis in coupling with type H vessel formation. Systemic injection of TGF-β neutralizing antibody using the methods of the present invention, effectively attenuated HO progression in multiple different HO animal models. The present invention provides methods for prophylaxis and treatment of HO and also rare genetic diseases such as fibrodysplasia ossificans progressive (FOP) (also known as myositis ossificans progressive) and progressive osseous heteroplasia (POH).by inhibition of TGF-β.

The present invention refers to the use of thiazolidinediones (preferably rosiglitazone and / or pioglitazone) in the prevention or treatment abnormal bone growth selected from the list comprising: heterotopic ossification, osteophytes and / or syndesmophytes. According to the present invention, thiazolidinediones can be combined with corticoids and / or anti-inflammatory drugs (preferably non-steroidal anti-inflammatory drugs).

A method for detecting and monitoring the progression of heterotopic ossification by Raman spectral analysis. Analysis of heterotopic ossification progress can be conducted using invasive or invasive means using specific Raman spectroscopy. Analysis is by determination of a number of Raman spectral parameters including the area under one or more of the vibrational bands, band area ratios, band height, ratios of band heights and shift in band center.

The present invention provides compositions and methods for inhibiting heterotopic ossification (HO) of a cell. Other embodiments of the invention include methods of treating a subject having heterotopic ossification or a subject at risk of developing HO, as well as methods for identifying a compound that inhibits heterotopic ossification (HO) of a cell.

The invention provides a method of treating heterotopic ossification in a subject in need thereof. The method comprises administering a hypoxia inducible factor-1α (Hif-1α) inhibitor to the subject. In various embodiments, the Hif-1α inhibitor is PX-478, rapamycin, or digoxin.

The invention provides a fluorescence real-time quantitative PRC detection kit for serum miR-630 and application of the miR-630. The miR-630 can be applied to the preparation of a kit used for obtaining early traumatic heterotopic ossification informatton; and the fluorescence real-time quantitative PRC detection kit for the serum miR-630 comprises a miR-630 specific primer and an internal reference U6 specific primer. The fluorescence real-time quantitative PRC detection kit for the serum miR-630 can rapidly and accurately detect the expression level of the miR-630 in target blood, thereby obtaining heterotopic ossification relevant information.

The invention belongs to the field of biological medicine, and relates to application of a CXCL12 / CXCR4 signal channel in preparation of a medicine for treating or preventing heterotopic ossification. According to the application disclosed by the invention, high expression of the ectopic new bone formation part CXCL12 in an ankylosing spondylitis (AS) patient and an AS related animal model is found for the first time, and after CXCR4 is inhibited by adopting plerixafor, ectopic osteogenesis of a mouse is obviously reduced. The invention also provides an application of the CXCL12 detection reagent in preparation of a heterotopic ossification detection reagent or kit, and an application of the CXCL12 / CXCR4 signal channel inhibitor in preparation of drugs for treating or preventing heterotopic ossification. Taking ankylosing spondylitis heterotopic ossification as an example, plerixafor has a good inhibition effect.